Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed LaborNCT05582135
Postoperative Analgesic Effect of Esketamine
A study testing 2 mg morphine sulfate, 0.25mg/kg esketamine and 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate in people with Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed Labor and Analgesia, run by Xuanhan County People's Hospital at 1 site in China.
Trial summary
The aim of this study was to determine whether the addition of esketamine to morphine would improve postoperative analgesia after caesarean section. Parturients who planned for a caesarean delivery using combined spinal-epidural anaesthesia with a request for postoperative anaesthesia were randomly divided into four… Read more about this study
- Who is it for?
- Ages 20 to 32 years, women only
- Conditions the study is for
- Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed Labor, Analgesia
- What is being tested?
- 2 mg morphine sulfate, 0.25mg/kg esketamine and 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 119 participants
- Where
- 1 siteChina
- Study dates
- 5 May 2021to 16 Aug 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 32 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- nulliparous parturients who scheduled for elective caesarean delivery under spinal-epidural anaesthesia;
- parturients who had requested postoperative analgesia;
- parturients aged between 20-35 years old;
- parturients who had a full-term pregnancy;
- parturients who were identified as having a singleton pregnancy; and
- parturients who were categorised as having an American Society of Anaesthesiologists (ASA) physical status
Who cannot join
- parturients with severe internal, surgical or obstetric comorbidities (including spinal deformities, hypertension, placental abruption, cholestasis in pregnancy, asthma, heart disease and abnormal coagulation parameters)
- parturients with a known allergy to the drugs used in this study
- parturients with severe mental illness who could not comply with doctors' instructions
- parturients with chronic pain syndrome, which is defined as pain that persists for a period longer than 3 months
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Epidural Esketamine and Morphine for Postoperative Analgesia After Caesarean Delivery: A Pilot Study
The aim of this study was to determine whether the addition of esketamine to morphine would improve postoperative analgesia after caesarean section.
Parturients who planned for a caesarean delivery using combined spinal-epidural anaesthesia with a request for postoperative anaesthesia were randomly divided into four groups (A, B, C and D). When the surgery was completed, the parturients in groups A, B, C and D were administered 2 mg morphine, 0.25mg/kg of esketamine, 0.25mg/kg of esketamine plus 2 mg morphine sulfate and 0.25mg/kg of esketamine plus 1 mg morphine through the epidural catheters, respectively. The postoperative pain at rest, pain with movement, the number of rescue analgesics and adverse effects were evaluated for 48 h after caesarean delivery.
- Conditions
- Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed Labor, Analgesia
- Being tested
- 2 mg morphine sulfate, 0.25mg/kg esketamine, 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate, 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
2 mg morphine sulfateDrug
The parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
0.25mg/kg esketamineDrug
The parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
0.25mg/kg of esketamine in combination with 2 mg morphine sulfateDrug
The parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
0.25mg/kg of esketamine in combination with 1 mg morphine sulfateDrug
The parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
| Study group | Role | What they receive |
|---|---|---|
| group A | Active comparator | The parturients in group A were administered 2 mg morphine sulfate through the epidural catheter. Receives: Drug: 2 mg morphine sulfate |
| group B | Active comparator | The parturients in group B were administered 0.25mg/kg of esketamine. Receives: Drug: 0.25mg/kg esketamine |
| group C | Active comparator | The parturients in group C were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate. Receives: Drug: 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate |
| group D | Active comparator | The parturients in group D were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate. Receives: Drug: 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative pain score at rest
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Two hours after caesarean delivery
Postoperative pain score at rest
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Four hours after caesarean delivery
Postoperative pain score at rest
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Eight hours after caesarean delivery
Postoperative pain score at rest
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Twelve hours after caesarean delivery
Postoperative pain score at rest
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Twenty-four hours after caesarean delivery
Postoperative pain score at rest
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Forty-eight hours after caesarean delivery
Postoperative pain score with movement
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Two hours after caesarean delivery
Postoperative pain score with movement
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Four hours after caesarean delivery
Postoperative pain score with movement
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Eight hours after caesarean delivery
Postoperative pain score with movement
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Twelve hours after caesarean delivery
Postoperative pain score with movement
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Twenty-four hours after caesarean delivery
Postoperative pain score with movement
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Measured: Forty-eight hours after caesarean delivery
number of rescue analgesics required
The number of rescue analgesics required within 48 h of surgery was recorded
Measured: within Forty-eight hours of surgery
Secondary outcomes (25)
systolic blood pressure (SBP)
Patient's systolic blood pressure (SBP)
Measured: Two hours after caesarean delivery
systolic blood pressure (SBP)
Patient's systolic blood pressure (SBP)
Measured: Four hours after caesarean delivery
systolic blood pressure (SBP)
Patient's systolic blood pressure (SBP)
Measured: Eight hours after caesarean delivery
systolic blood pressure (SBP)
Patient's systolic blood pressure (SBP)
Measured: Twelve hours after caesarean delivery
systolic blood pressure (SBP)
Patient's systolic blood pressure (SBP)
Measured: Twenty-four hours after caesarean delivery
systolic blood pressure (SBP)
Patient's systolic blood pressure (SBP)
Measured: Forty-eight hours after caesarean delivery
diastolic blood pressure (DBP)
Patient's diastolic blood pressure (DBP)
Measured: Two hours after caesarean delivery
diastolic blood pressure (DBP)
Patient's diastolic blood pressure (DBP)
Measured: Four hours after caesarean delivery
diastolic blood pressure (DBP)
Patient's diastolic blood pressure (DBP)
Measured: Eight hours after caesarean delivery
diastolic blood pressure (DBP)
Patient's diastolic blood pressure (DBP)
Measured: Twelve hours after caesarean delivery
diastolic blood pressure (DBP)
Patient's diastolic blood pressure (DBP)
Measured: Twenty-four hours after caesarean delivery
diastolic blood pressure (DBP)
Patient's diastolic blood pressure (DBP)
Measured: Forty-eight hours after caesarean delivery
heart rate (HR)
Patient's heart rate (HR)
Measured: Two hours after caesarean delivery
heart rate (HR)
Patient's heart rate (HR)
Measured: Four hours after caesarean delivery
heart rate (HR)
Patient's heart rate (HR)
Measured: Eight hours after caesarean delivery
heart rate (HR)
Patient's heart rate (HR)
Measured: Twelve hours after caesarean delivery
heart rate (HR)
Patient's heart rate (HR)
Measured: Twenty-four hours after caesarean delivery
heart rate (HR)
Patient's heart rate (HR)
Measured: Forty-eight hours after caesarean delivery
Blood oxygen saturation (SpO2)
Measurement of pulse Blood oxygen saturation (SpO2) in parturients
Measured: Two hours after caesarean delivery
Blood oxygen saturation (SpO2)
Measurement of pulse Blood oxygen saturation (SpO2) in parturients
Measured: Four hours after caesarean delivery
Blood oxygen saturation (SpO2)
Measurement of pulse Blood oxygen saturation (SpO2) in parturients
Measured: Eight hours after caesarean delivery
Blood oxygen saturation (SpO2)
Measurement of pulse Blood oxygen saturation (SpO2) in parturients
Measured: Twelve hours after caesarean delivery
Blood oxygen saturation (SpO2)
Measurement of pulse Blood oxygen saturation (SpO2) in parturients
Measured: Twenty-four hours after caesarean delivery
Blood oxygen saturation (SpO2)
Measurement of pulse Blood oxygen saturation (SpO2) in parturients
Measured: Forty-eight hours after caesarean delivery
Adverse events
Adverse events that occurred after the administration of study drugs were also recorded.
Measured: within Forty-eight hours of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Oct 2022
- Study start5 May 2021
- Primary completion16 Aug 2021
- Study completion16 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed LaborStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 119 participants (actual)
Sponsor and investigators
- Lead sponsor
- Xuanhan County People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05582135
- Sponsor's protocol ID
- XuanhanCo
- Status last verified
- Oct 2022
- First submitted
- 12 Oct 2022
- Last updated
- 17 Oct 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epidural Esketamine and Morphine for Postoperative Analgesia After Caesarean Delivery: A Pilot Study
- ClinicalTrials.gov ID
- NCT05582135
- Acronym / sponsor ID
- XuanhanCo
- Conditions
- Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed Labor, Analgesia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 119 participants (actual)
- Lead sponsor
- Xuanhan County People's HospitalUniversity, hospital or other
- Study start
- 5 May 2021 (actual)
- Primary completion
- 16 Aug 2021 (actual)
- Study completion
- 16 Aug 2021 (actual)
- First posted
- 17 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to determine whether the addition of esketamine to morphine would improve postoperative analgesia after caesarean section.
Parturients who planned for a caesarean delivery using combined spinal-epidural anaesthesia with a request for postoperative anaesthesia were randomly divided into four groups (A, B, C and D). When the surgery was completed, the parturients in groups A, B, C and D were administered 2 mg morphine, 0.25mg/kg of esketamine, 0.25mg/kg of esketamine plus 2 mg morphine sulfate and 0.25mg/kg of esketamine plus 1 mg morphine through the epidural catheters, respectively. The postoperative pain at rest, pain with movement, the number of rescue analgesics and adverse effects were evaluated for 48 h after caesarean delivery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| group A | Active comparator | Drug: 2 mg morphine sulfateThe parturients in group A were administered 2 mg morphine sulfate through the epidural catheter. |
| group B | Active comparator | Drug: 0.25mg/kg esketamineThe parturients in group B were administered 0.25mg/kg of esketamine. |
| group C | Active comparator | Drug: 0.25mg/kg of esketamine in combination with 2 mg morphine sulfateThe parturients in group C were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate. |
| group D | Active comparator | Drug: 0.25mg/kg of esketamine in combination with 1 mg morphine sulfateThe parturients in group D were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate. |
Who may qualify
- Ages
- 20 to 32 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- nulliparous parturients who scheduled for elective caesarean delivery under spinal-epidural anaesthesia;
- parturients who had requested postoperative analgesia;
- parturients aged between 20-35 years old;
- parturients who had a full-term pregnancy;
- parturients who were identified as having a singleton pregnancy; and
Key exclusion criteria (4 listed)
- parturients with severe internal, surgical or obstetric comorbidities (including spinal deformities, hypertension, placental abruption, cholestasis in pregnancy, asthma, heart disease and abnormal coagulation parameters)
- parturients with a known allergy to the drugs used in this study
- parturients with severe mental illness who could not comply with doctors' instructions
- parturients with chronic pain syndrome, which is defined as pain that persists for a period longer than 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 2 mg morphine sulfateThe parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL. | Drug | group A |
| 0.25mg/kg esketamineThe parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL. | Drug | group B |
| 0.25mg/kg of esketamine in combination with 2 mg morphine sulfateThe parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL. | Drug | group C |
| 0.25mg/kg of esketamine in combination with 1 mg morphine sulfateThe parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL. | Drug | group D |
Primary outcome
Postoperative pain score at rest
Time frame: Two hours after caesarean delivery
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score at rest
Time frame: Four hours after caesarean delivery
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score at rest
Time frame: Eight hours after caesarean delivery
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score at rest
Time frame: Twelve hours after caesarean delivery
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score at rest
Time frame: Twenty-four hours after caesarean delivery
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score at rest
Time frame: Forty-eight hours after caesarean delivery
The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score with movement
Time frame: Two hours after caesarean delivery
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score with movement
Time frame: Four hours after caesarean delivery
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score with movement
Time frame: Eight hours after caesarean delivery
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score with movement
Time frame: Twelve hours after caesarean delivery
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score with movement
Time frame: Twenty-four hours after caesarean delivery
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
Postoperative pain score with movement
Time frame: Forty-eight hours after caesarean delivery
The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain.
number of rescue analgesics required
Time frame: within Forty-eight hours of surgery
The number of rescue analgesics required within 48 h of surgery was recorded
25 secondary outcomes
systolic blood pressure (SBP)
Time frame: Two hours after caesarean delivery
systolic blood pressure (SBP)
Time frame: Four hours after caesarean delivery
systolic blood pressure (SBP)
Time frame: Eight hours after caesarean delivery
systolic blood pressure (SBP)
Time frame: Twelve hours after caesarean delivery
systolic blood pressure (SBP)
Time frame: Twenty-four hours after caesarean delivery
systolic blood pressure (SBP)
Time frame: Forty-eight hours after caesarean delivery
diastolic blood pressure (DBP)
Time frame: Two hours after caesarean delivery
diastolic blood pressure (DBP)
Time frame: Four hours after caesarean delivery
diastolic blood pressure (DBP)
Time frame: Eight hours after caesarean delivery
diastolic blood pressure (DBP)
Time frame: Twelve hours after caesarean delivery
diastolic blood pressure (DBP)
Time frame: Twenty-four hours after caesarean delivery
diastolic blood pressure (DBP)
Time frame: Forty-eight hours after caesarean delivery
heart rate (HR)
Time frame: Two hours after caesarean delivery
heart rate (HR)
Time frame: Four hours after caesarean delivery
heart rate (HR)
Time frame: Eight hours after caesarean delivery
heart rate (HR)
Time frame: Twelve hours after caesarean delivery
heart rate (HR)
Time frame: Twenty-four hours after caesarean delivery
heart rate (HR)
Time frame: Forty-eight hours after caesarean delivery
Blood oxygen saturation (SpO2)
Time frame: Two hours after caesarean delivery
Blood oxygen saturation (SpO2)
Time frame: Four hours after caesarean delivery
Blood oxygen saturation (SpO2)
Time frame: Eight hours after caesarean delivery
Blood oxygen saturation (SpO2)
Time frame: Twelve hours after caesarean delivery
Blood oxygen saturation (SpO2)
Time frame: Twenty-four hours after caesarean delivery
Blood oxygen saturation (SpO2)
Time frame: Forty-eight hours after caesarean delivery
Adverse events
Time frame: within Forty-eight hours of surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Oct 2022.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 2 mg morphine sulfate, 0.25mg/kg esketamine and 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate in people with Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed Labor and Analgesia, run by Xuanhan County People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative pain score at rest (time frame: Two hours after caesarean delivery). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Oct 2022.